Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Thrixen logo — Unlocking the next generation of simple, affordable & access...

Thrixen

Unlocking the next generation of simple, affordable & accessible diagnostics

Founded 2021 Singapore Singapore 10 employees Venture round Total: $7.00M Biotechnology, Health Care

General Information

Company Name Thrixen
Founded Year 2021
Location Singapore Singapore
Founders / Decision Makers
Team member
Employees 10
Industries Biotechnology, Health Care
Funding Stage Venture round
Business Model B2B, Platform, White Label
Revenue Model Licensing, Product Sales, Project Based
Social

BounceWatch is an independent company data service, not affiliated with Thrixen. To contact Thrixen, visit thrixen.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Thrixen compare?

A PDF of Thrixen and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Thrixen soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Thrixen

Thrixen is a biotech/Medtech startup founded in 2021 and based in Singapore. With the slogan "Unlocking the next generation of simple, affordable & accessible diagnostics," Thrixen is dedicated to revolutionizing diagnostic technology for biomarker detection at the chemistry level. The company's aim is to unlock the next generation of diagnostic and health care monitoring tools that are simple and accessible at the point of care/need. Thrixen's innovative approach positions it at the forefront of the biotechnology industry, offering promising potential for disruptive advancements in healthcare. As of now, there is no publicly disclosed information about Thrixen's last investment or the investors involved. Thrixen's focus on advancing diagnostic technology and simplifying health care monitoring holds significant promise for addressing global health challenges.

Business keywords: biotech, medtech, diagnostic technology, biomarker detection, healthcare monitoring, rapid diagnostic test, protein engineering, multiplexing, point of care, next-generation diagnostics, accessible healthcare, chemistry technology, innovation

Services & Products

Development of multiplex point-of-care diagnostics platform
Bioengineered binder production and licensing
Portable diagnostic device manufacturing
Comprehensive clinical testing solutions

Target Customers

Healthcare Providers Clinical Laboratories Biotech and Pharma Companies Research Institutions Medical Device Distributors

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $7.00M 2
22Health Ventures, John Ballantyne
29 Apr 2024

Thrixen Alternatives & Competitors

View All Alternatives
Thrixen vs
Omini
Omini France

Multiplex blood testing platform to monitor chronic diseases like heart failure Project co-funded by...

58 employees
Biotechnology, Health Care
Compare Thrixen vs Omini
Thrixen vs
BIOPIX DNA TECHNOLOGY S.A.
BIOPIX DNA TECHNOLOGY S.A. Greece

Diagnostic solutions on the front lines of healthcare, enabling lab-quality testing anytime, anywher...

Seed
16 employees
Biotechnology, Health Care
Thrixen vs
Kenota Health
Kenota Health Canada

Next generation medical devices. Kenota Health makes allergy testing safe, simple and certain.

Series A
29 employees
Biotechnology, Health Care
Compare Thrixen vs Kenota Health
View all alternatives

FAQ About Thrixen

Unlocking the next generation of simple, affordable & accessible diagnostics
Thrixen was founded in 2021.
Thrixen is headquartered in Singapore.
Thrixen operates in Biotechnology and Health Care. Its work centres on biotech, medtech, diagnostic technology and biomarker detection. Its customers include Healthcare Providers, Clinical Laboratories and Biotech and Pharma Companies.
Thrixen has a B2B, Platform and White Label business model. Its revenue comes from Licensing, Product Sales and Project Based.
Thrixen has approximately 10 employees.
Thrixen has completed 1 funding round, raising a total of $7.00M. The latest funding stage is Venture round.
Thrixen offers: Development of multiplex point-of-care diagnostics platform, Bioengineered binder production and licensing, Portable diagnostic device manufacturing, Comprehensive clinical testing solutions.
Top alternatives and competitors to Thrixen include Omini, BIOPIX DNA TECHNOLOGY S.A., Kenota Health, AmplifiDx, Rivaara Labs. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Thrixen and Omini are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Thrixen, https://www.bouncewatch.com/company/thrixen, updated 29 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout